


Minibinder-Drug Conjugates Targeting Human EpCAM and PDL1 Receptors for Targeted Cancer Therapy

This technology offers a set of novel polypeptides designed to bind to human EpCAM and PDL1 receptors, offering potential applications in treating cancer, autoimmune diseases, and inflammation.



Technology ID

BDP 8525

Category

Therapeutics/Oncology Selection of Available Technologies Therapeutics/Other

Authors

David Baker

Learn more



What is the Problem?

Cancer, autoimmune diseases, and inflammation are significant health challenges worldwide. Current treatments often have limitations, including side effects, resistance, and lack of specificity. Human epithelial cell adhesion molecule (EpCAM) and programmed death-ligand 1 (PDL1) receptors have been linked to a wide range of these diseases. As a result, therapeutics targeting these receptors can lead to more targeted and effective treatments.

What is the Solution?

The solution is a set of novel polypeptides that bind specifically to human EpCAM and PDL1 receptors. EpCAM and PDL1 are proteins often overexpressed in various diseases, including cancer. By binding to these receptors, the mini-protein binders can potentially interfere with disease progression, offering a new approach to treatment.

What is the Competitive Advantage?

These polypeptides offer a targeted approach to disease treatment, potentially reducing side effects associated with less specific therapies. They could be used alone or in combination with existing treatments, enhancing therapeutic efficacy. This technology represents a promising step forward in the development of targeted therapies for cancer, autoimmune diseases, and inflammation.

Patent Information:

WO2023212629A2